NEW YORK (GenomeWeb News) – Prometheus Laboratories has licensed US rights to Rosetta Genomics' recently introduced microRNA-based tests and has taken an equity stake in the molecular diagnostics firm.

San Diego-based Prometheus has gained the right to sell the miRview mets, miRview squamous, and miRview meso, which Rosetta launched in late 2008. It will provide Rosetta with payments, either in the form of milestones or R&D funding, and royalties based on net sales in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.